May 29, 2022 05:34 (IST)
Follow us:
Molnupiravir Laurus Labs signs agreement with MPP for manufacturing Molnupiravir
Mumbai/UNI: Hyderabad-based Laurus Labs Limited on Friday said that it has signed an agreement with MPP (Medicine Patent Pool) for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir.
Commenting on the development, Dr Satyanarayana Chava, Founder and CEO, Laurus Labs said, "We are happy to sign an agreement to manufacture the oral Covid-19 antirviral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission."
Latest Headlines
Fuel prices remain unchanged Sat, May 28 2022
Twitter co-founder Jack Dorsey steps down from board of directors Sat, May 28 2022
Nykaa's Q4FY22 PAT falls 58 pc YoY to Rs76 million; revenue from ops grows 31 pc to Rs9,733 million Fri, May 27 2022
Indian Rupee closes at 77.56 against USD Fri, May 27 2022
Tech Mahindra moves up 4.10 pc to Rs 1,123.55 Fri, May 27 2022
Indian Market: Sensex up 632.13 pts Fri, May 27 2022
High WPI inflation to impact retail inflation: RBI Fri, May 27 2022